Allen Cheryl, Kortagere Sandhya, Tong Huaxiang, Matthiesen Robert A, Metzger Joseph I, Wiemer David F, Holstein Sarah A
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York (C.A.); Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania (S.K.); Penn State Cancer Institute, Hershey, Pennsylvania (H.T.); Department of Chemistry, University of Iowa, Iowa City, Iowa (R.A.M., J.I.M., D.F.W.); and Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska (S.A.H.).
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York (C.A.); Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania (S.K.); Penn State Cancer Institute, Hershey, Pennsylvania (H.T.); Department of Chemistry, University of Iowa, Iowa City, Iowa (R.A.M., J.I.M., D.F.W.); and Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska (S.A.H.)
Mol Pharmacol. 2017 Mar;91(3):229-236. doi: 10.1124/mol.116.107326. Epub 2017 Jan 5.
The isoprenoid donor for protein geranylgeranylation reactions, geranylgeranyl diphosphate (GGDP), is the product of the enzyme GGDP synthase (GGDPS) that condenses farnesyl diphosphate (FDP) and isopentenyl pyrophosphate. GGDPS inhibition is of interest from a therapeutic perspective for multiple myeloma because we have shown that targeting Rab GTPase geranylgeranylation impairs monoclonal protein trafficking, leading to endoplasmic reticulum stress and apoptosis. We reported a series of triazole bisphosphonate GGDPS inhibitors, of which the most potent was a 3:1 mixture of homogeranyl (HG) and homoneryl (HN) isomers. Here we determined the activity of the individual olefin isomers. Enzymatic and cellular assays revealed that although HN is approximately threefold more potent than HG, HN is not more potent than the original mixture. Studies in which cells were treated with varying concentrations of each isomer alone and in different combinations revealed that the two isomers potentiate the induced-inhibition of protein geranylgeranylation when used in a 3:1 HG:HN combination. A synergistic interaction was observed between the two isomers in the GGDPS enzyme assay. These results suggested that the two isomers bind simultaneously to the enzyme but within different domains. Computational modeling studies revealed that HN is preferred at the FDP site, that HG is preferred at the GGDP site, and that both isomers may bind to the enzyme simultaneously. These studies are the first to report a set of olefin isomers that synergistically inhibit GGDPS, thus establishing a new paradigm for the future development of GGDPS inhibitors.
用于蛋白质香叶基香叶基化反应的类异戊二烯供体香叶基香叶基二磷酸(GGDP),是香叶基香叶基二磷酸合酶(GGDPS)的产物,该酶可将法尼基二磷酸(FDP)和异戊烯基焦磷酸缩合。从治疗多发性骨髓瘤的角度来看,GGDPS抑制是有意义的,因为我们已经表明,靶向Rab GTPase香叶基香叶基化会损害单克隆蛋白运输,导致内质网应激和细胞凋亡。我们报道了一系列三唑双膦酸盐GGDPS抑制剂,其中最有效的是均香叶基(HG)和均壬基(HN)异构体的3:1混合物。在这里,我们确定了各个烯烃异构体的活性。酶促和细胞试验表明,虽然HN的效力比HG高约三倍,但HN并不比原始混合物更有效。对细胞单独用不同浓度的每种异构体以及不同组合进行处理的研究表明,当以3:1的HG:HN组合使用时,这两种异构体可增强对蛋白质香叶基香叶基化的诱导抑制作用。在GGDPS酶试验中观察到这两种异构体之间存在协同相互作用。这些结果表明,这两种异构体同时结合到酶上,但在不同的结构域内。计算模型研究表明,HN在FDP位点更受青睐,HG在GGDP位点更受青睐,并且两种异构体可能同时结合到酶上。这些研究首次报道了一组协同抑制GGDPS的烯烃异构体,从而为GGDPS抑制剂的未来开发建立了新的范例。